Related Experiment Videos
Technetium-99m tetrofosmin scintigraphy in pediatric osteogenic sarcoma
Orazio Schillaci1, Angela Spanu, Francesco Scopinaro
1University of Rome Tor Vergata, Viale G. Mazzini 121, I-00195 Rome, Italy. oschil@tiscalinet.it
Oncology Reports
|April 10, 2003
Summary
Technetium-99m tetrofosmin scintigraphy shows promise for detecting osteosarcoma and monitoring chemotherapy response. This imaging technique may help predict treatment effectiveness by assessing tumor necrosis non-invasively.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Technetium-99m tetrofosmin (TF) is primarily a myocardial perfusion agent.
- TF has demonstrated potential as a tumor-seeking tracer.
- Assessing response to preoperative chemotherapy (PC) is crucial for osteosarcoma curability.
Purpose of the Study:
- To preliminarily assess TF scintigraphy for osteosarcoma detection.
- To evaluate TF's utility in monitoring response to PC.
- To correlate TF uptake with tumor necrosis for prognostic insight.
Main Methods:
- Fourteen patients with newly diagnosed osteosarcoma underwent TF scintigraphy.
- Dynamic and static imaging were performed post-injection.
- Quantitative analysis using lesion (L) to normal tissue (N) ratios compared pre- and post-chemotherapy scans.
Main Results:
- TF scintigraphy effectively detected osteosarcoma with rapid tumoral uptake.
- The mean L/N ratio at 20 minutes was 2.76±1.05.
- Changes in L/N ratio post-chemotherapy correlated significantly with tumor necrosis percentage.
Conclusions:
- TF scintigraphy is a viable method for detecting osteosarcoma.
- Preliminary findings suggest TF can non-invasively predict response to PC.
- Larger studies are needed to confirm TF's role in predicting treatment outcomes.